<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of Pharmacy and Health Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPHR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2321-3647</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.46624/ajphr.2021.v9.i10.001</article-id>
      <article-id pub-id-type="publisher-id">AJPHR910001</article-id>
      <title-group>
        <article-title>A Review on Nanocarriers Third Generation As Targeted Delivery Systems for Cancer Therapy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chandira</surname>
            <given-names>R. Margret</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Babu</surname>
            <given-names>B.Anish</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>B.S.Venkateswarlu</surname>
            <given-names>B.S.Venkateswarlu</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Professor,</aff>
      <pub-date pub-type="epub" iso-8601-date="2021-10-01">
        <month>10</month>
        <day>01</day>
        <year>2021</year>
      </pub-date>
      <volume>9</volume>
      <issue>10</issue>
      <abstract>
        <p>ABSTRACTCancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Nanomaterials are at the cutting edge of the rapidly developing area of nanotechnology. The potential for nanoparticles in cancer drug delivery is infinite with novel new applications constantly being explored. Targeted nanoparticles play a very significant role in cancer drug delivery. The promising implications of these platforms for advances in cancer diagnostics and therapeutics form the basis of this review. Targeted delivery systems of nano biomaterials are necessary to be developed for the diagnosis and treatment of cancer. Nano-based pharmaceuticals, or nanomedicines,” are engineered to either function as a drug or carry a drug while addressing these scientific challenges due to their nano-size. Keywords: Nanomaterials, nanomedicines, Targeted delivery</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Nanomaterials</kwd>
        <kwd>nanomedicines</kwd>
        <kwd>Targeted delivery</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
